Cantor Fitzgerald Brokers Raise Earnings Estimates for AARD

Aardvark Therapeutics, Inc. (NASDAQ:AARD - Free Report) - Stock analysts at Cantor Fitzgerald raised their FY2025 earnings estimates for shares of Aardvark Therapeutics in a research report issued to clients and investors on Thursday, May 15th. Cantor Fitzgerald analyst J. Schimmer now forecasts that the company will post earnings of ($2.46) per share for the year, up from their prior estimate of ($2.49). Cantor Fitzgerald has a "Overweight" rating and a $50.00 price objective on the stock.

A number of other equities research analysts also recently issued reports on the stock. Royal Bank of Canada cut their price objective on shares of Aardvark Therapeutics from $21.00 to $20.00 and set an "outperform" rating for the company in a research report on Thursday, May 15th. Bank of America boosted their price objective on shares of Aardvark Therapeutics from $22.00 to $26.00 and gave the company a "buy" rating in a research report on Thursday, March 27th. Morgan Stanley initiated coverage on shares of Aardvark Therapeutics in a research report on Monday, March 10th. They set an "overweight" rating and a $29.00 price objective for the company. Finally, Wall Street Zen downgraded shares of Aardvark Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $31.25.

Aardvark Therapeutics Price Performance

Shares of AARD stock traded up $0.49 during mid-day trading on Monday, reaching $10.50. 22,053 shares of the company's stock traded hands, compared to its average volume of 112,131. Aardvark Therapeutics has a 12 month low of $4.88 and a 12 month high of $19.58. The firm's 50 day moving average price is $9.11.

Aardvark Therapeutics (NASDAQ:AARD - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.70) by ($0.01).

Institutional Trading of Aardvark Therapeutics

Hedge funds have recently bought and sold shares of the stock. Goldman Sachs Group Inc. purchased a new stake in shares of Aardvark Therapeutics in the first quarter valued at $153,000. Adage Capital Partners GP L.L.C. bought a new position in Aardvark Therapeutics in the 1st quarter worth about $1,878,000. Walleye Capital LLC purchased a new stake in shares of Aardvark Therapeutics in the first quarter valued at approximately $88,000. Cormorant Asset Management LP bought a new position in shares of Aardvark Therapeutics during the 1st quarter worth $6,009,000. Finally, Braidwell LP purchased a new position in Aardvark Therapeutics during the 1st quarter valued at about $3,755,000.

About Aardvark Therapeutics

Aardvark Therapeutics, Inc operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.